Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
- Study Type:
- EXPANDED_ACCESS
- Last Updated:
- 2021-08-13
Conditions
- Non-Small Cell Lung Cancer
- Medullary Thyroid Cancer
Interventions
- DRUG
No Results Yet